News

Mycenax Granted Exclusive Rights to RIN Institute’s Proprietary ADC Linker Patents for CDMO Services

Mycenax, Kidswell Bio and Chiome Bioscience Enter into Master Service Agreement for Development of New Biosimilar Drugs

Mycenax Partners to Establish Japan's Domestic Biosimilar Manufacturing Facilities

Mycenax Commences Commercial Manufacturing for Our First Internationally Approved Biopharmaceutical

Mycenax and Sartorius Join Forces to Enhance Biopharmaceutical Manufacturing Solutions

Mycenax and Apexcella collaborate to Advance Commercialization of Allogeneic Natural Killer Cell Therapies to Benefiting More Patients

Opening Ceremony of Mycenax's New Automated Fill-Finish Line

MYCENAX and CHITOSE Join Forces to Forge a New Era of Cell Line Development

Taiwan’s Regenerative Medicine Acts passed, MYCENAX CDMO Services Are Ready!

Merck Signs MoU with Mycenax Biotech to Drive Innovation in Bioprocessing Technology